David Lee
Cardiovascular Disease · Columbia, MONPI 1528553492
Payments from drug & device makers
Across 224 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novartis$912
- Abbott$444
- E.r. Squibb & Sons, L.L.C.$367
- Chiesi USA, Inc.$359
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$284
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,20287%
- Education$60612%
- Gifts$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 37 | $1,052 |
| Novartis | 88 | $912 |
| Abbott | 4 | $444 |
| E.r. Squibb & Sons, L.L.C. | 16 | $367 |
| Chiesi USA, Inc. | 11 | $359 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $284 |
| AstraZeneca | 6 | $230 |
| Alnylam Pharmaceuticals Inc. | 7 | $166 |
| Johnson & Johnson | 9 | $156 |
| Merck | 3 | $130 |
| Lexicon Pharmaceuticals, Inc. | 1 | $115 |
| Bridgebio Pharma, Inc. | 1 | $112 |
| ZOLL Circulation Inc | 1 | $100 |
| Abiomed | 3 | $94 |
| La Jolla Pharmaceutical Company | 3 | $72 |
| Pfizer | 3 | $49 |
| Lundbeck LLC | 1 | $27 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Medtronic | 2 | $25 |
| Altathera Pharmaceuticals LLC | 1 | $25 |
| Novo Nordisk | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $21 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
| Harmony Biosciences LLC | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENSITE$418
- Repatha$386
- WAINUA$116
- Inpefa$115
- Attruby$112
- TherOx DS2 Console$100
- Catheter$100
- Downstream Cartridge$100
How this compares
$4,854 in reported general payments places this provider in the 60th percentile of 391 cardiovascular disease providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $13,109 |
| ClopidogrelClopidogrel Bisulfate | 11 | $369 |
| Ezetimibe | 14 | $220 |
| Rosuvastatin Calcium | 17 | $139 |
| Carvedilol | 16 | $68 |
| Furosemide | 15 | $54 |
| Amlodipine Besylate | 12 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $23 | $13,10914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Columbia
- James FairlambColumbia$373K
- Brian BostickColumbia$147K
- Patrice DelafontaineColumbia$138K
- Sudarshan BallaColumbia$101K
- James ElliottColumbia$83K
- Tillmann CyrusColumbia$47K
- Cristina DanilaColumbia$32K
- Mikhail KosiborodKansas City$27.8M
- Mohammad TahirSaint Louis$2.7M
- John SpertusKansas City$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.